Conmed (CNMD) Aandeel Koers
Conmed Koers
In de afgelopen 19 jaar liet Conmed de omzet jaarlijks met 4,0% groeien tot 1,37 Miljard USD. De winst per aandeel is de afgelopen 18 jaar met 0,3% per jaar gegroeid. Bij Conmed is de nettowinstmarge met 3,4% ten opzichte van 6,2% enkele jaren geleden gedaald. Op de huidige koers komt het dividendrendement uit op ongeveer 1,23%. De uitkeringsratio ligt rond 40% van de winst. Het consensus-koersdoel voor Conmed op 12 maanden bedraagt 37,50 USD, circa 23,1% onder de huidige koers. Van de 12 analisten geven 0 het aandeel een koopadvies — per saldo een Houden-consensus.
Conmed aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Conmed bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Conmed
Conmed Corp is a leading global medical technology company. Its business model revolves around offering a wide range of surgical products and services to healthcare professionals worldwide. The company specializes in the development, manufacturing, and marketing of innovative surgical devices and equipment. With a focus on minimally invasive procedures, Conmed Corp aims to enhance patient outcomes and reduce healthcare costs. By providing solutions for areas such as electrosurgery, endosurgery, and orthopedic surgery, Conmed Corp continues to drive advancements in the medical field. This commitment to delivering high-quality products and advancing medical technologies solidifies its position as a trusted industry leader.
Conmed Corp is primarily active in the medical devices industry.
The main competitors of Conmed Corp in the market include Medtronic, Johnson & Johnson, Stryker Corporation, and Smith & Nephew.
Conmed Corp. is a renowned medical technology company with a rich history and strong background. Founded in 1970, Conmed Corp. has been dedicated to providing innovative surgical solutions and equipment to healthcare professionals worldwide. With its headquarters in Utica, New York, the company has grown to become a leading player in the field of minimally invasive procedures. Conmed Corp. offers a wide range of products, including surgical instruments, endoscopic technologies, and electrosurgical systems, designed to enhance patient outcomes and streamline healthcare processes. With a focus on research and development, Conmed Corp. continues to shape the future of surgical advancements and improve the standard of patient care.
Conmed Corp has achieved several significant milestones throughout its history. The company has successfully established itself as a leading global medical technology provider, specializing in surgical devices and equipment. Conmed Corp has expanded its product portfolio and enhanced its research and development efforts to cater to a wide range of medical specialties. The company has also received numerous accolades and recognition for its innovative solutions and commitment to improving patient outcomes. With its relentless dedication to advancing clinical education and training, Conmed Corp has become a trusted name in the healthcare industry, ensuring enhanced surgical techniques and superior patient care.
Conmed Corp is primarily present in various countries and regions across the globe. The company has a significant presence in the United States, where its headquarters is located. Additionally, Conmed Corp has established a strong market presence in Europe, especially in countries like Germany, France, and the United Kingdom. The company also operates in Asian markets, including China and Japan, and has a growing presence in emerging markets such as India and Brazil. Furthermore, Conmed Corp has a global distribution network, allowing its products and services to reach healthcare facilities worldwide.
Conmed Corp represents a commitment to delivering innovative medical solutions. With a strong corporate philosophy centered around the core values of integrity, quality, and customer focus, the company aims to improve patient outcomes. Conmed Corp is dedicated to maintaining high ethical standards, fostering a culture of continuous improvement, and promoting teamwork and collaboration. By combining cutting-edge technology with a patient-centric approach, Conmed Corp strives to provide healthcare professionals with advanced tools and services that address the evolving needs of the medical community.
Analisten hanteren momenteel een gemiddeld koersdoel van 37,50 USD voor het aandeel Conmed (mediaan: 37,50 USD), oftewel -23,1 % ten opzichte van de laatste koers. De consensus is gebaseerd op 12 analistenratings.
12 analisten beoordelen het aandeel Conmed momenteel: 0 adviseren kopen, 8 houden en 4 verkopen. Voor 2026 verwachten analisten dat Conmed een omzet van 1,37 Miljard USD en winst per aandeel van 4,55 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Conmed op 43,52 EUR (48,75 USD).
Het aandeel Conmed (CNMD) is genoteerd aan 5 beurzen, waaronder: NYSE (CNMD), SIX (Zürich) (EC8.SW), Frankfurt (EC8.F), München (EC8.MU), Düsseldorf (EC8.DU).
Conmed Corporation is a multinational provider of medical devices and instruments used in orthopedics, gastroenterology, endoscopy, laparoscopy, and other medical fields. The company is headquartered in Utica, New York, and operates in more than 30 countries. Conmed has a diverse business segment that focuses on three main categories: Surgical Instruments, Endoscopy, and Electrosurgery. These three divisions offer various products tailored to the specific needs of surgeons and other medical professionals. The Surgical Instruments division includes a wide range of products such as scissors, forceps, needle holders, scalpels, retractors, and other specialized surgical instruments. These instruments are used in a variety of surgical procedures to ensure precision and safety. Endoscopy is an increasingly important field of study in medicine. Here, Conmed offers a range of products such as endoscopes, capsule endoscopes, endoscopic ultrasound probes, and endoscopy accessories. Endoscopes allow doctors to examine internal organs and tissues, reducing the costs and risks associated with traditional surgery. The Electrosurgery division includes products such as generators, active electrodes, monopolar instruments, bipolar instruments, and accessories. Electrosurgery is used in many surgical procedures to cut, coagulate, or remove tissue. Conmed's products enable surgeons to quickly and effectively remove tissue without causing damage to healthy tissue. Conmed's products are used by a variety of medical professionals in various medical fields. The company also provides excellent customer support, ensuring that surgeons and medical professionals can receive assistance at any time. Conmed has introduced the following products on the market: - Hall Zimmer Surgical PowerTools: The system offers electrically powered surgical hand drills, saws, grinders, and other surgical instruments for orthopedics. - Edge Bipolar Clamping System: This is a bipolar instrument system with a universal cable that can be used in many different surgical procedures. - PRO360 Digital Laparoscopy System: A complete endoscopic device system that provides clear, high-resolution imaging for laparoscopy. - EndoRotor Medical Endoscopy Cleaner: This device allows endoscopy systems to be cleaned, disinfected, and sterilized in a simpler and more effective way. Conmed has a robust service and support system aimed at maintaining customer trust and loyalty. Furthermore, Conmed continuously strives to acquire new knowledge and improve its technology to provide surgeons and other medical professionals with the best instruments and products to enhance their success rate and patient outcomes. Overall, Conmed has a first-class business model that helps medical professionals make their work more effective and safer. The company puts its expertise and technology at the service of the healthcare community and is committed to the safety of its customers and their patients. Answer: Conmed Corporation is a multinational provider of medical devices and instruments used in various medical fields such as orthopedics, gastroenterology, and endoscopy. The company focuses on three main categories: Surgical Instruments, Endoscopy, and Electrosurgery. They offer a wide range of products tailored to the specific needs of surgeons and other medical professionals. Conmed aims to provide reliable customer support and continuously improve their technology to enhance the success and safety of medical procedures.
De verwachte omzet van Conmed bedraagt 1,37 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Conmed bedraagt 141,28 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Conmed bedraagt momenteel 10,71. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Conmed-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Conmed bedraagt momenteel 1,11. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Conmed-aandeel.
De Eulerpool Kwaliteitsscore voor Conmed is 5/10.
De ISIN van Conmed is US2074101013. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Conmed is 886793. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Conmed is CNMD. Onder dit beurstickersymbool wordt het Conmed-aandeel op de beurs verhandeld.
Conmed aandeel
Conmed Peer Group
Conmed Ticker
Conmed FIGI
Alle fundamentals en diepgaande analyse van Conmed
Onze aandelenanalyse van het Conmed-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Conmed. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: